#pkmodeling search results

A new study demonstrates how exposure-response modeling can be used to determine the optimal dose of pemigatinib for the treatment of cholangiocarcinoma: ➡ bit.ly/49IPmWG #Pharmacokinetic #PKmodeling @ASCPT_ClinPharm

InsightRX's tweet image. A new study demonstrates how exposure-response modeling can be used to determine the optimal dose of pemigatinib for the treatment of cholangiocarcinoma: 

➡ bit.ly/49IPmWG #Pharmacokinetic #PKmodeling @ASCPT_ClinPharm

Neutralizing ADA = noisy data. Don’t let it cloud your PK insights. Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species. Actionable tips + Phoenix® NLME in action. Register: certara.com/webinar/pharma… #ADA #PKModeling

Certara's tweet image. Neutralizing ADA = noisy data. Don’t let it cloud your PK insights.
Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species.
Actionable tips + Phoenix® NLME in action.
Register: certara.com/webinar/pharma…
#ADA #PKModeling

Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts! She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS @tamuvetmed #pkmodeling

tamusuperfund's tweet image. Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts!  She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS  @tamuvetmed #pkmodeling

Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment

VeriSIMlife's tweet image. Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment

Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0

VeriSIMlife's tweet image. Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0

Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment

VeriSIMlife's tweet image. Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment

Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT. Enjoyed listening to other amazing speakers, as well. @PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth

sadhussen's tweet image. Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT.

Enjoyed listening to other amazing speakers, as well.

@PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth
sadhussen's tweet image. Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT.

Enjoyed listening to other amazing speakers, as well.

@PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth

Which #PKmodeling approach is right for your program? Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh #PremierResearch #ModelInformedDrugDevelopment

premierresearch's tweet image. Which #PKmodeling approach is right for your program?

Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh

#PremierResearch #ModelInformedDrugDevelopment

Check out my former-labmate/mentor/therapist Dr. Naveen Mehta's excellent work published in @natBME nature.com/articles/s4155…. Main takeaway: when designing cancer vaccines, don't forget to consider their pharmacokinetics--it makes a difference! #ProteinEngineering #PKmodeling


Join me at ACCP (WA) on 9/11 for Symposium 7; 1:30-5 pm. Excited to present the results of our recent analysis on PK modeling in FIH dose selection of IO products. Don't miss out on this opportunity to learn about our findings. #ACCP2023 #oncology #PKModeling #FIHdoseselection


Our Pediatric Early Development Symposium is a can’t miss event featuring engaging & educational sessions like Pharmacokinetic Modeling, which will address questions like: How are PBPK & PopPK models qualified/validated? Register today buff.ly/389Dxds #pkmodeling #pkdata


Open for a LTD time only - articles from themed Issue on #Nanomedicine from #PKmodeling to tox effects bit.ly/1MuW3fV


Which #PKmodeling approach is right for your program? Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh #PremierResearch #ModelInformedDrugDevelopment

premierresearch's tweet image. Which #PKmodeling approach is right for your program?

Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh

#PremierResearch #ModelInformedDrugDevelopment

Neutralizing ADA = noisy data. Don’t let it cloud your PK insights. Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species. Actionable tips + Phoenix® NLME in action. Register: certara.com/webinar/pharma… #ADA #PKModeling

Certara's tweet image. Neutralizing ADA = noisy data. Don’t let it cloud your PK insights.
Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species.
Actionable tips + Phoenix® NLME in action.
Register: certara.com/webinar/pharma…
#ADA #PKModeling

Join me at ACCP (WA) on 9/11 for Symposium 7; 1:30-5 pm. Excited to present the results of our recent analysis on PK modeling in FIH dose selection of IO products. Don't miss out on this opportunity to learn about our findings. #ACCP2023 #oncology #PKModeling #FIHdoseselection


Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0

VeriSIMlife's tweet image. Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0

Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment

VeriSIMlife's tweet image. Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment

Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment

VeriSIMlife's tweet image. Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment

Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts! She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS @tamuvetmed #pkmodeling

tamusuperfund's tweet image. Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts!  She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS  @tamuvetmed #pkmodeling

Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT. Enjoyed listening to other amazing speakers, as well. @PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth

sadhussen's tweet image. Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT.

Enjoyed listening to other amazing speakers, as well.

@PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth
sadhussen's tweet image. Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT.

Enjoyed listening to other amazing speakers, as well.

@PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth

Our Pediatric Early Development Symposium is a can’t miss event featuring engaging & educational sessions like Pharmacokinetic Modeling, which will address questions like: How are PBPK & PopPK models qualified/validated? Register today buff.ly/389Dxds #pkmodeling #pkdata


Check out my former-labmate/mentor/therapist Dr. Naveen Mehta's excellent work published in @natBME nature.com/articles/s4155…. Main takeaway: when designing cancer vaccines, don't forget to consider their pharmacokinetics--it makes a difference! #ProteinEngineering #PKmodeling


Open for a LTD time only - articles from themed Issue on #Nanomedicine from #PKmodeling to tox effects bit.ly/1MuW3fV


Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts! She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS @tamuvetmed #pkmodeling

tamusuperfund's tweet image. Congratulations to post-doc trainee Dr. Chimeddulam Dalaijamts!  She has accepted a Senior Analyst position at Intercept Pharmaceuticals - she'll be doing what she loves most - PK modeling in clinical pharmacology. @SRP_NIEHS  @tamuvetmed #pkmodeling

A new study demonstrates how exposure-response modeling can be used to determine the optimal dose of pemigatinib for the treatment of cholangiocarcinoma: ➡ bit.ly/49IPmWG #Pharmacokinetic #PKmodeling @ASCPT_ClinPharm

InsightRX's tweet image. A new study demonstrates how exposure-response modeling can be used to determine the optimal dose of pemigatinib for the treatment of cholangiocarcinoma: 

➡ bit.ly/49IPmWG #Pharmacokinetic #PKmodeling @ASCPT_ClinPharm

Neutralizing ADA = noisy data. Don’t let it cloud your PK insights. Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species. Actionable tips + Phoenix® NLME in action. Register: certara.com/webinar/pharma… #ADA #PKModeling

Certara's tweet image. Neutralizing ADA = noisy data. Don’t let it cloud your PK insights.
Join our webinar to see how Certara scientists model ADA-driven variability for better dose prediction—across species.
Actionable tips + Phoenix® NLME in action.
Register: certara.com/webinar/pharma…
#ADA #PKModeling

Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment

VeriSIMlife's tweet image. Check out our blog post from earlier this month, "An In-Depth Guide to Pharmacokinetic Modeling." hubs.li/Q01wjq400 #pkmodeling #biotech #drugdevelopment

Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0

VeriSIMlife's tweet image. Pleased to share that VeriSIM Life CSO Dr. Szczepan Baran is a member of the NIH working group on Novel Alternative Models, advising on reducing/refining animal studies in drug research. #AI #AnimalResearch #pkmodeling hubs.li/Q01BfzGq0

Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment

VeriSIMlife's tweet image. Quantifying how a drug moves into, through, and out of the body is at the heart of pharmacokinetic modeling (PK), helping inform many aspects of the drug development process. Read our latest blog post to learn more: bit.ly/3UTtE9K #pkmodeling #biotech #drugdevelopment

Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT. Enjoyed listening to other amazing speakers, as well. @PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth

sadhussen's tweet image. Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT.

Enjoyed listening to other amazing speakers, as well.

@PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth
sadhussen's tweet image. Excited to talk @AdeliadePharmacology Scientific meeting #research .Personalised therapy is the key to mitigate risks with HRT.

Enjoyed listening to other amazing speakers, as well.

@PIDG_UniSA @UniversitySA @UniSACRI #3Dprinting #pkmodeling #womenshealth

Which #PKmodeling approach is right for your program? Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh #PremierResearch #ModelInformedDrugDevelopment

premierresearch's tweet image. Which #PKmodeling approach is right for your program?

Our latest blog compares NCA, PopPK/PD, and PBPK modeling—highlighting when to use each for maximum impact in MIDD: bit.ly/4fzp1xh

#PremierResearch #ModelInformedDrugDevelopment

Loading...

Something went wrong.


Something went wrong.


United States Trends